Recombinant Mouse Pcsk9 Protein, His-tagged

• Cat.No.: Pcsk9-412M
• Product Overview: Recombinant Mouse Pcsk9 protein with His tag was expressed in HEK293.

Specification

• Description: Enables apolipoprotein binding activity; lipoprotein particle binding activity; and low-density lipoprotein particle receptor binding activity. Involved in several processes, including cellular response to insulin stimulus; cellular response to starvation; and regulation of neuron apoptotic process. Acts upstream of or within several processes, including low-density lipoprotein receptor particle metabolic process; regulation of low-density lipoprotein particle receptor catabolic process; and triglyceride metabolic process. Located in COPII-coated ER to Golgi transport vesicle; endoplasmic reticulum; and extracellular space. Is expressed in several structures, including alimentary system; cerebellum; genitourinary system; liver; and telencephalon. Human ortholog(s) of this gene implicated in familial hypercholesterolemia and hypobetalipoproteinemia. Orthologous to human PCSK9 (proprotein convertase subtilisin/kexin type 9).
• Source: HEK293
• Species: Mouse
• Tag: His
• Form: Lyophilized
• Molecular Mass: 72 kDa
• Protein length: 694
• AA Sequence: MGTHCSAWLRWPLLPLLPPLLLLLL LLCPTGAGAQDEDGDYEELMLALPS QEDGLADEAAHVATATFRRCSKEAW RLPGTYIVVLMEETQRLQIEQTAHR LQTRAARRGYVIKVLHIFYDLFPGF LVKMSSDLLGLALKLPHVEYIEEDS FVFAQSIPWNLERIIPAWHQTEEDR SPDGSSQVEVYLLDTSIQGAHREIE GRVTITDFNSVPEEDGTRFHRQASK CDSHGTHLAGVVSGRDAGVAKGTSL HSLRVLNCQGKGTVSGTLIGLEFIR KSQLIQPSGPLVVLLPLAGGYSRIL NAACRHLARTGVVLVAAAGNFRDDA CLYSPASAPEVITVGATNAQDQPVT LGTLGTNFGRCVDLFAPGKDIIGAS SDCSTCFMSQSGTSQAAAHVAGIVA RMLSREPTLTLAELRQRLIHFSTKD VINMAWFPEDQQVLTPNLVATLPPS THETGGQLLCRTVWSAHSGPTRTAT ATARCAPEEELLSCSSFSRSGRRRG DWIEAIGGQQVCKALNAFGGEGVYA VARCCLVPRANCSIHNTPAARAGLE THVHCHQKDHVLTGCSFHWEVEDLS VRRQPALRSRRQPGQCVGHQAASVY ASCCHAPGLECKIKEHGISGPSEQV TVACEAGWTLTGCNVLPGASLTLGA YSVDNLCVARVHDTARADRTSGEAT VAAAICCRSRPSAKASWVQ
• Purity: > 98%
• Applications: WB; ELISA; FACS; FC
• Stability: This bioreagent is stable at 4 centigrade (short-term) and -70 centigrade(long-term). After reconstitution, sample may be stored at 4 centigrade for 2-7 days and below -18 centigrade for future use.
• Storage: At -20 centigrade.
• Concentration: 1 mg/mL
• Storage Buffer: PBS (pH 7.4-7.5). Sterile-filtered colorless solution.
• Reconstitution: Reconstitute in sterile distilled H2O to no less than 100 μg/mL; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.

Gene Information

• Gene Name: Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Mus musculus (house mouse) ]
• Official Symbol: Pcsk9
• Synonyms: PCSK9; proprotein convertase subtilisin/kexin type 9; NARC-1; convertase subtilisin; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; neural apoptosis-regulated convertase 1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409
• Gene ID: 100102
• mRNA Refseq: NM_153565
• Protein Refseq: NP_705793
• UniProt ID: https://www.uniprot.org/uniprotkb/Q80W65/entry

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.